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An effective immune response against infectious
agents involves massive expansion of CD8+ T cells.
Once the infection is cleared, the majority of these
effector cells die through unknown mechanisms.
How is expansion controlled to maximize pathogen
clearance and minimize immunopathology? We
found, after Listeria infection, plasma transforming
growth factor b (TGF-b) titers increased concomitant
with the expansion of effector CD8+ T cells. Blocking
TGF-b signaling did not affect effector function of
CD8+ T cells. However, TGF-b controlled effector
cell number by lowering Bcl-2 amounts and selec-
tively promoting the apoptosis of short-lived effector
cells. TGF-b-mediated apoptosis of this effector
subpopulation occurred during clonal expansion
and contraction, whereas interleukin-15 (IL-15)
promoted their survival only during contraction. We
demonstrate that the number of effector CD8+
T cells is tightly controlled by multiple extrinsic
signals throughout effector differentiation; this plas-
ticity should be exploited during vaccine design
and immunotherapy against tumors and autoim-
mune diseases.
INTRODUCTION
Encounter with foreign antigen induces naive T cells to expand
massively, a process called clonal expansion, and differentiate
into effector T cells. The high proliferative capacity and cytotoxic
activity of antigen-activated CD8+ T cells requires an effective
control of their life span in order to maintain lymphocyte homeo-
stasis and to avoid immunopathology. A contraction period
follows clonal expansion, during which time the majority of
effector cells die rapidly by apoptosis (Hand and Kaech, 2008;
Marrack and Kappler, 2004). A small proportion of effector cells
survives and further differentiates into long-lived memory cells
(Kaech and Wherry, 2007). Increasing the quantity and quality
of memory CD8+ T cells is crucial to improving the efficacy of
most vaccines (Seder et al., 2008). Another important focus in
the vaccine field is to generate enhanced expansion of effectorcells because of the direct relationship between the number of
effector cells at the peak of expansion and the final number of
memory cells that are formed (Hou et al., 1994; Murali-Krishna
et al., 1998). However, very little is known about the signals
that influence the pool size of the effector cells.
Recent elegant work has described multiple subpopulations of
effector CD8+ T cells that exist during clonal expansion in res-
ponse to some viral and bacterial infections (Joshi et al., 2007;
Sarkaret al., 2008). Thesubsetof effectorCD8+Tcells that survive
and becomememory cells are sometimes referred to as memory
precursor effector cells (MPECs), whereas the population that
dies during contraction is referred to as short-lived effector cells
(SLECs) (Joshi et al., 2007; Joshi and Kaech, 2008). Both of these
populations have been shown to have very similar functional
ability at the peak of the immune response; however, they greatly
differ in their memory potential and survivability (Joshi et al.,
2007; Sarkar et al., 2008). A major challenge that remains is to
identify extrinsic and intrinsic signals that make SLECs suscep-
tible to apoptosis and the signals that promote the survival and
maintenance of the MPECs (Hand and Kaech, 2008).
The common gammachain cytokines interleukin-2, -7, and -15
(IL-2, IL-7, and IL-15) are critical regulators of activated T cell
proliferation, survival, and memory T cell formation (Boyman
et al., 2007; Ma et al., 2006; Malek, 2008). IL-2 is a secreted cyto-
kine that binds trimeric receptors made up of IL-2Ra (CD25), the
b receptor (CD122), and the common g-chain (cgc) receptor on
the surface of target cells. IL-2 plays an important role in the
differentiation and early expansion of a functional effector popu-
lation and is required for secondary expansion of memory CD8+
T cells, but does not seem to cause the contraction of effector
T cells (Blattman et al., 2003; D’Souza and Lefrancois, 2003;
Williams et al., 2006). IL-7 is also a secreted cytokine that binds
to thedimeric IL-7Ra (CD127) and thecgc receptor on thesurface
of target cells (Ma et al., 2006). Effector T cells with high expres-
sionof the IL-7Raduring acute infections are consideredmemory
precursor cells (Joshi and Kaech, 2008; Kaech and Wherry,
2007). However, transgenic overexpression of IL-7Ra had no
effect on effector or memory T cell survival, demonstrating that
the IL-7Ra expression does not instruct the formation of memory
T cells by allowing them to better compete for IL-7 (Hand et al.,
2007; Haring et al., 2008). Thus, the downregulation of IL-7Ra
appears to be an indicator of reducedmemoryCD8+ T cell poten-
tial but is not the major cause of effector T cell death after acute
infections such as LCMV and Listeria (Hand and Kaech, 2008).
IL-15 is a membrane-bound cytokine that is presented in transImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 131
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TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 1. TGF-b Signaling May Be Important
for Controlling the Number and Function of
Effector CD8+ T Cells
(A) Splenocytes from 6-week-old mice under
steady-state conditions were gated on CD8+
T cells. Data shown are representative of at least
10 different sets of mice with similar profiles.
(B) 5 3 104 naive OTI-Rag1/ cells were adop-
tively transferred into wild-type B6 hosts, and OTI
cell expansion in response to LM-OVA infection
was measured in a longitudinal experiment. Data
are plotted as the fraction of OTI cells among
25,000 total peripheral blood lymphocytes (PBLs).
Average and SD of 4 mice is shown.
(C) Total TGF-b levels detected with ELISA after
acidification of plasmacollected from infectedmice
from part (B).on the surface of monocytes or dendritic cells by the IL-15Ra
(Ma et al., 2006). Cells that express the b receptor CD122 and
the cgc receptor can respond to trans-presented IL-15 and trans-
duce IL-15 signaling through this complex (Burkett et al., 2003;
Dubois et al., 2002). More recent work indicates that in response
to someacute infections, the survival ofMPECsdepends on both
IL-7 and IL-15, whereas the survival of SLECs depends on IL-15
because these cells lack IL-7Ra (Joshi et al., 2007; Rubinstein
et al., 2008; Yajima et al., 2006). In addition, exogenous adminis-
tration of IL-2 or IL-15 greatly improves the survival of SLECs
during contractionwithout inducing their proliferation (Rubinstein
et al., 2008). In line with these observations, it is thought that
SLECs die for reasons other than sole deprivation from these
cytokines, although the extrinsic signals that further promote
the apoptosis of SLECs have not yet been identified (Joshi and
Kaech, 2008).
Transforming growth factor b (TGF-b) is a pleiotropic cytokine
with potent regulatory activity (Li and Flavell, 2008a, 2008b;
Li et al., 2006b). Monomeric TGF-b binds to TGF-b receptor II
(TGF-bRII), triggering the kinase activity of the cytoplasmic
domain that in turn activates TGF-bRI. The activated receptor
complex leads to nuclear translocation of Smad molecules and
transcription of target genes (Li et al., 2006b). To understand
the role of TGF-b signaling in T cell biology, we developed
a mouse model where the expression of a dominant-negative
form of TGF-bRII (DNR), lacking the kinase domain, inhibits
TGF-b signaling in both CD4+ and CD8+ T cells (Gorelik and
Flavell, 2000). T cells in this model expand at a higher rate,
acquire an activated phenotype, and produce effector cytokines,
and the mice eventually succumb to autoimmunity (Gorelik and
Flavell, 2000). Via this and other mouse models, the pivotal func-
tion of TGF-b under steady-state conditions has been identified
tomaintain tolerance through the regulation of lymphocyte prolif-
eration, differentiation, and survival (Gorelik and Flavell, 2000;
Li and Flavell, 2008a, 2008b). It is known that the regulatory
activity of TGF-b is modulated based on the cell type, its differ-
entiation state, expression of costimulatory molecules, and the132 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.presence of other cytokines (Li and Flavell, 2008a, 2008b;
Li et al., 2006b). However, the role of TGF-b in controlling
CD8+ T cell activation, proliferation, differentiation, and survival
has not been addressed under infectious conditions.
We show here that blockade of TGF-b signaling during effector
T cell differentiation did not alter ex vivo cytokine production and
in vivo CTL activity of CD8+ effector T cells. Surprisingly, we
found that clonally expanding CD8+ T cells underwent massive
apoptosis even before reaching the ‘‘contraction’’ phase.
However, blockade of TGF-b signaling on effector CD8+ T cells
caused an increase in their total number, which was a result of
reduced apoptosis of short-lived effector cells during clonal
expansion. We further demonstrate that TGF-b provides an
extrinsic signal to further downregulate Bcl-2 expression in
effector cells and selectively promote the apoptosis of SLECs.
Finally, we present evidence for a model in which TGF-b and
IL-15 provide opposing extrinsic signals to control the number
of SLECs during clonal expansion and contraction. These find-
ings identify a unique role for TGF-b in controlling the number
of clonally expanding effector CD8+ T cells under acute inflam-
matory conditions. The relevance and implications of these find-
ings for vaccine design and potential immunotherapy against
tumors and certain autoimmune diseases are further discussed.
RESULTS
Systemic Increase in TGF-b Expression at the Peak
of T Cell Proliferation during Listeria Infection
Overexpression of a dominant-negative form of TGF-b receptor
II specifically in T cells under the control of the CD4 promoter
(CD4-DNR), lacking the CD8 silencer, results in the accumulation
of CD44hi effector-memory T cells (Figure 1A, top; Gorelik and
Flavell, 2000). These observations, and numerous other studies,
underline the importance of TGF-b in maintaining peripheral
tolerance under steady-state conditions (Li and Flavell, 2008a,
2008b; Li et al., 2006b). However, the biological role of TGF-b
during an acute infection is still poorly understood. To assess
Immunity
TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 2. An Increase in the Number of OTI-
DNR Compared to OTI Cells at the Peak of
CD8+ T Cell Clonal Expansion in Response
to LM-OVA
(A) 2.5 3 104 each of naive OTI-Rag1/CD45.1.1
and OTI-DNR-Rag1/CD45.1.2 cells were adop-
tively cotransferred into naive hosts, followed by
infection with LM-OVA 1 day later. The absolute
number of each OTI and OTI-DNR population
from each organ is plotted over time. For the blood
measurements, the number of OTI cells per 1 ml of
blood is plotted. Data are representative of two
independent experiments with similar results.
(B and C) Cotransfer and infection was performed
as in (A), except the same group of mice were bled
for a longitudinal experiment to compare the
kinetics of OTI and OTI-DNR T cell accumulation
among PBLswhilemeasuring plasma TGF-b levels
in the same infected mice. Average and SD is
shown. Data are representative of two indepen-
dent experiments with similar results and a total
of 10–15 mice in each experiment.whether TGF-b plays a role in CD8+ T cell biology during an acute
infection, we adoptively transferred 53 104 naive OTI transgenic
T cells, expressing OVA257-264 K
b-specific TCR, into wild-type
mice and infected them 1 day later with recombinant Listeria
monocytogenes-expressing OVA (LM-OVA). OTI T cell expan-
sion was measured among the peripheral blood lymphocytes
(Figure 1B), and total TGF-b was measured from blood plasma
(Figure 1C). The observation that plasma TGF-b rise during an
acute infection with similar kinetics to the accumulation of
CD8+ T cells prompted us to further investigate the role of
TGF-b in effector T cell development and function.
Blockade of TGF-b Signaling in CD8+ T Cells Results
in Enhanced Accumulation of Effector Cells
To obtain large numbers of antigen-specific naive CD8+ T cells
that express the TGF-bRII DNR, we crossed the CD4-DNR
mice onto OTI transgenic mice and further crossed them onto
a Rag1/ and CD45.1 congenic marker (Figure 1A, bottom).
Unlike the original CD4-DNR mice (Figure 1A, top; Gorelik and
Flavell, 2000), the OTI-DNR-Rag1/ (OTI-DNR) mice do not
develop autoimmunity, and large numbers of antigen-specific
naive (CD62Lhi-CD44lo) T cells can be isolated from young
mice (Figure 1A, bottom). To address the role of TGF-b signaling
during CD8+ T cell differentiation and effector generation in
response to an acute infection, we wanted to perform competi-
tive adoptive cotransfer of OTI and OTI-DNR naive cells into the
same host followed by in vivo activation via LM-OVA. Further, we
employed low numbers (around 25,000 sorted naive CD8+ T cells
of each type) to avoid the artifacts that can accompany transfers
of too many cells (Marzo et al., 2005).
DNR-bearing T cells cannot be adoptively transferred into
C57Bl/6 mice, because they are immunologically rejected
because they contain human rather than mouse DNR sequence
(Figure S1 available online). Instead, we used our CD11c-DNR
mice as recipients of adoptive transfers (Laouar et al., 2005).
These mice express the same human TGF-bRII DNR transgene
in dendritic cells and natural killer cells under the control of the
CD11c promoter and therefore are immunologically tolerant tothe human DNR sequence. These mice have been well charac-
terized and no observable defect has been detected in any of
the T cell compartments (Laouar et al., 2005). Nevertheless, to
control for any untoward effects of the CD11c-DNR transgene
on the data, all of the experiments involving adoptive transfers
were performed side by side with transfers of wild-type OTI cells
into both CD11c-DNR transgene-positive and -negative mice.
For the remainder of this study, the main figures contain the
comparison of OTI and OTI-DNR cells transferred into the
CD11c-DNR hosts (labeled as ‘‘host’’), whereas the accompa-
nying supplemental figures contain the same analysis of the
OTI cells transferred into transgene-negative wild-type litter-
mates. It is noteworthy that no substantial difference was
observed in our studies between the results obtained when
OTI cells were transferred into either host.
WhenOTI andOTI-DNRcellswere cotransferred andactivated
with LM-OVA, a massive (3-fold) increase in the number of
OTI-DNR effector cellswas observed in blood and both lymphoid
and nonlymphoid organs (Figures 2A and 2B). To assure that
this difference was not somehow related to a substantial reduc-
tion in the amount of antigen present during priming in the
CD11c-DNR mice, we measured bacterial burden 3 days after
infection. We detected similar numbers of bacteria in the spleen
and liver of wild-type and CD11c-DNR mice that had no trans-
genic Tcells or hadbeenadoptively transferredwitheither 53104
OTI or OTI-DNR cells (data not shown). Notably, the difference
between OTI and OTI-DNR cell numbers became apparent only
after day 5 postinfection (p.i.) (Figure 2B). This also suggests
that the difference in OTI-DNR accumulation is not related to
a difference in priming and activation of the transgenic T cells.
Similar to infection in wild-type hosts (Figure 1C), a 3-fold
increase in the amount of plasma TGF-b was also detected in
the CD11c-DNR recipients during the peak of T cell proliferation
(Figure 2C). Remarkably, the time at which the difference in the
expansion between OTI and OTI-DNR cells first becomes
apparent (around day 6 postinfection) directly correlated with
the time at which plasma TGF-b also peaked during the course
of infection, suggesting a direct effect of TGF-b on the numberImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 133
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TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 3. Blockade of TGF-b Signaling Does Not Alter Cytokine Production and CTL Activity of Effector CD8+ T Cells
(A) Adoptive cotransfer and LM-OVA infection was performed as described in Figure 2A. Intracellular cytokine staining of spleen cells isolated 7 days p.i. Host
(CD45.2.2), OTI (CD45.1.1), and OTI-DNR (CD45.1.2) cells were identified based on staining with CD8 and the corresponding congenic markers. Splenocytes
were stimulated with or without SIINFEKL peptide. One representative histogram is shown.
(B) Average and SD of four different cotransfers. Data are representative of three independent experiments with similar results.
(C) In vivo CTL assay performed with effector OTI and OTI-DNR cells isolated from the spleen of infected mice 7 days p.i. Representative raw data are shown on
the left. Summary of two independent experiments is shown on the right, with average and SD of 4 recipients of each population.
(D) Relative mRNA expression of cytolytic molecules from day 7 effector cells. Samples were first normalized to HPRT. Relative fold increase over naive OTI cells
is shown. Data are average and SD of three independent experiments.of effector CD8+ T cells. TGF-b amounts in the plasma dropped
by the middle of the contraction phase and returned to baseline
by 2 weeks postinfection. Collectively, these data suggest that
TGF-b does not play a major role during the early phases of
CD8+ T cell priming and activation, but rather, that it plays
a key role in determining the number of effector T cells at the
peak of clonal expansion.
Blockade of TGF-b Signaling Does Not Alter Effector
Function of CD8+ T Cells upon Listeria Infection
Many studies have suggested that under steady-state condi-
tions or in the presence of tumors, TGF-b inhibits cytokine
production and CTL activity of CD8+ T cells (Ahmadzadeh and
Rosenberg, 2005; Li et al., 2006a; Marie et al., 2006; Thomas
and Massague, 2005; Trapani, 2005). To address whether
TGF-b plays a similar role during effector T cell differentiation
in response to an acute infection, we compared ex vivo cytokine
production and in vivo CTL activity of effector OTI and OTI-DNR
cells that were generated in the same host (Figure 3). No signif-134 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.icant difference in granzyme B, TNF, or IL-2 production was
observed between OTI and OTI-DNR day 7 effector T cells
when restimulated ex vivo with SIINFEKL peptide (Figures 3A
and 3B; Figure S2A). OTI-DNR cells contained a larger popula-
tion of the low-IFN-g producing effector cells, which resulted in
slightly lower average mean fluorescent intensity of the whole
population (Figures 3A and 3B, compare histogram to bar
graphs). To compare CTL activity of OTI and OTI-DNR effector
T cells, day 7 effectors were isolated by cell sorting and the
same number of each effector population was retransferred
into naive hosts along with different ratios of target cells, and
specific lysis was measured in vivo (Figure 3C). Once again, no
difference was observed in the cytolytic activity of OTI and
OTI-DNR effector cells (Figure 3C; Figure S2B). These findings
were consistent with similar mRNA expression of both granzyme
B and perforin in the OTI and OTI-DNR effector cells (Figure 3D).
Collectively, these data suggest that TGF-b does not play amajor
role in inhibiting the effector function of CD8+ T cells under acute
Listeria infection conditions.
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TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 4. TGF-b Promotes Apoptosis of Effector CD8+ T Cells during Clonal Expansion
(A) Histograms showing BrdU incorporation of clonally expanding OTI and OTI-DNR cells from cotransfer experiments. Splenocytes were first gated on CD8+
T cells, and host, OTI, and OTI-DNR subpopulations were separated based on congenic markers.
(B) Pair-wise comparison of each subpopulation in four different animals with varying degrees of BrdU incorporation. Data are representative of three independent
experiments with similar results.
(C) Dead versus apoptotic cells from day 5 (PBL) and day 7 (spleen) of infectedmice were identified by AnnexinV and PI staining. OTI andOTI-DNR cells were then
separated based on congenic markers among the PI population. Average and SD of 3 (day 5) and 4 (day 7) mice per group is shown.TGF-b Promotes the Apoptosis of Effector CD8+ T Cells
When TGF-b signaling was blocked in CD8+ effector T cells,
a 3-fold higher number of effector T cells accumulated at the
peak of clonal expansion in vivo (Figure 2). T cell accumulation
is a result of the combination of T cell death and proliferation,
and it has been suggested that TGF-b can inhibit T cell prolifer-
ation and induce apoptosis of activated T cells under a variety of
in vitro conditions (Marrack and Kappler, 2004; Sillett et al., 2001;
Wolfraim et al., 2004). Therefore, we asked whether blockade of
TGF-b signaling in vivo would enhance the proliferative ability of
effector T cells, promote their better survival, or both. The prolif-
eration of OTI versus OTI-DNR cells was measured by the incor-
poration of BrdU near the peak of clonal expansion in adoptive
cotransfer experiments (Figure 4A; Figure S3A). Although the
range in BrdU incorporation differed in each individual mouse,
we observed a consistent increase in BrdU incorporation in
OTI-DNR compared to OTI cells (Figure 4B). It is generally
thought that T cells proliferate during clonal expansion and die
only during the contraction phase (Marrack and Kappler, 2004;
Williams and Bevan, 2007). Contrary to this, we observed
massive apoptosis of OTI cells on day 5 postinfection
(Figure 4C; Figure S3B) at the time when T cells are still clonally
expanding. However, the OTI-DNR effector cells, in the same
host, were mostly protected from the apoptosis that occurred
during (day 5) and at the peak of (day 7) clonal expansion
(Figure 4C). These data suggest that blockade of TGF-b signal-ing allows better proliferation of effector CD8+ T cells, but most
importantly, it protects OTI-DNR cells from the massive
apoptosis that occurs during clonal expansion.
Selective Accumulation of SLECs at the Peak of Clonal
Expansion in the Absence of TGF-b Signaling
Survival of effector CD8+ T cells is highly dependent on many
cell-intrinsic and -extrinsic factors including signaling from the
receptors of the cgc cytokines IL-2, IL-7, and IL-15. As a result,
many changes occur in the surface expression of the receptors
for these cytokines during effector CD8+ T cell differentiation
(Boyman et al., 2007; Kaech and Wherry, 2007; Masopust
et al., 2004; Williams and Bevan, 2007). Because we have shown
previously that TGF-b can modulate the expression of CD122,
via regulating T-bet in CD4+ Th1 cells (Li et al., 2006a), we
wanted to see whether the receptor expression for the cgc cyto-
kines was altered on effector CD8+ OTI-DNR compared to OTI
cells, resulting in their better survival. Similar to the expansion
phenotype, we did not find any difference in surface expression
of any of the molecules we analyzed on days 4 or 5 postinfection
(Figure 5A; Figure S4A), including complete downregulation of
CD25 on both OTI and OTI-DNR cells by day 5 postinfection
(data not shown). However, a difference in the upregulation of
CD127, the IL-7Ra chain, was observed starting at day 7 postin-
fection that also persisted into the early memory phase
(Figure 5B). In contrast, no difference was detected in theImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 135
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TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 5. Selective Apoptosis of SLECs by TGF-b
(A) Phenotypic comparisons between OTI and OTI-DNR effector CD8+ T cells. Histograms comparing the expression of each surface molecule on host CD8+
(solid gray), OTI (dashed line), and OTI-DNR (black line) T cells from cotransfer experiments. Data are representative of more than four independent experiments
with similar results.
(B) Expression pattern of indicated surface receptors was analyzed on OTI and OTI-DNR CD8+ T cells isolated from peripheral blood of LM-OVA-infected mice at
the indicated time points. Data are average and SD of 3–5 individual cotransfers and represents 1 out of 3 independent experiments with similar results.
(C) Representative diagram of each effector subpopulation separated based on CD127 and KLRG1 expression and the terminology used to describe each
subset.
(D) Representation of the difference seen in the percentages of OTI and OTI-DNR SLECs and MPECs isolated from the spleen of infected mice at the indicated
time points. Time point 2 days p.i. refers to naive cells prior to adoptive transfer.
(E) Bar graphs (top) comparing the absolute number of total and each OTI and OTI-DNR subpopulation from the spleen of infected mice at each indicated time
point. Longitudinal graphs (bottom) comparing the contribution of each subpopulation, on the same scale, to the overall increase in the number of OTI-DNR
effector cells. Data are average and SD of 2–3 mice per time point and represents 1 out of 2 independent experiments with similar results.expression of CD122 and IL-15Ra between OTI and OTI-DNR
cells throughout effector T cell differentiation (Figure 5B). Similar
to CD127, we also observed a difference in the upregulation of
CD27 starting at day 7 postinfection, whereas the expression
of CD62L and CD43 remained the same between the OTI and
OTI-DNR cells (Figure 5A, bottom; Figure S4A).
It has recently been shown that CD127 and killer cell lectin-like
receptor subfamily G1 (KLRG1) can be used to differentiate
between two types or subsets of differentiating effector CD8+
T cells. Memory precursor effector cells (MPECs) are enriched
in the KLRG1lo-CD127hi population, and short-lived effector cells
(SLECs) are enriched in the KLRG1hi-CD127lo and CD27lo popu-136 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.lation (Joshi et al., 2007; Sarkar et al., 2008). Because we
observed a larger fraction of CD127lo and CD27lo cells among
the OTI-DNR cells at the peak of clonal expansion (Figures 5A
and 5B), we hypothesized that blockade of TGF-b signaling
may be altering the differentiation and/or the survival of MPECs
and SLECs. To test this hypothesis, we determined the absolute
numbers of each OTI and OTI-DNR effector subpopulation,
based on CD127 and KLRG1 expression, throughout effector
differentiation (Figures 5C–5E; Figures S4B and S4C). OTI-DNR
cells had a higher percentage of SLECs (KLRG1hi-CD127lo) and
a lower percentage of MPECs (KLRG1lo-CD127hi) compared to
OTI cells (Figure 5D). However, when these percentages were
Immunity
TGF-b Promotes Apoptosis of Effector CD8+ T CellsFigure 6. TGF-b Promotes the Apoptosis of Effector CD8+ T Cells both Ex Vivo and In Vitro
(A) TGF-bRII expression on naive and effector OTI andOTI-DNR subpopulations. After adoptive cotransfer and LM-OVA infection, OTI andOTI-DNR cells isolated
from the spleen of infected mice were stained with CD127 and KLRG1 and either TGF-bRII or the isotype control antibodies. MFI of TGF-bRII was determined by
subtracting theMFI of background staining observed with isotype control, which varied from 3 to 6, from theMFI of TGF-bRII staining on the same subpopulation
of effector cells.
(B) After adoptive cotransfer and LM-OVA infection, day 7 spleens were isolated and a fraction of the splenocytes was cultured in media plus 2.5 ng/ml of TGF-b,
while a similar fraction was just cultured in media alone for 16 hr. OTI and OTI-DNR cells were then stained with antibodies to congenic markers and CD127-
KLRG1. The percent of live cells was determined in each fraction and the ratio of the percent live cells from TGF-b-treated cells is plotted over percent live cells
of untreated cells for each subpopulation. Average and SD of four experimental wells is shown. Data are representative of 1 out of 2 independent experiments.
(C) Forward and side scatter plots and CFSE dilution of OTI and OTI-DNR cells after being stimulated for 48 hr with SIINFEKL-loaded APCs (top). Cells were
washed and cultured in the absence or presence of 5 ng/ml of TGF-b and 20 ng/ml of IL-15, IL-7, or IL-2 for another 4 days. FACS plots represent total cell
recovery and show all the events collected within 1 min. AnnexinV+ (dead or apoptotic) and AnnexinV (live) and the CFSE dilution of each fraction is shown.
Data are representative of 1 out of 3 independent experiments with similar results.converted to absolute numbers for each subpopulation in the
spleen of infected mice, it became evident that the number of
MPECs remained similar between OTI and OTI-DNR cells,
whereas there were almost six times more OTI-DNR SLECs
compared to OTI SLECs at the peak of clonal expansion (Fig-
ure 5E, top). The contribution of the OTI-DNR SLEC subpopula-
tion to the overall increase of the total number of OTI-DNR cells
is most evident when the subpopulations are plotted on the
same scale (Figure 5E, bottom). These data suggest that TGF-b
signaling on effector CD8+ T cells selectively promotes the
apoptosis of SLECs.
Despite a Low Degree of TGF-bRII Expression,
TGF-b Can Promote the Apoptosis of SLECs Ex Vivo
We next wanted to explore the mechanism by which TGF-b
exerts its apoptotic effects selectively on SLECs and not on
MPECs. One obvious explanation for this selective mechanismmay lie within differential expression of TGF-b receptor on the
different subpopulations. Therefore, we measured and com-
pared TGF-bRII surface expression on naive and effector
subpopulations of OTI and OTI-DNR cells and found very high
expression of TGF-bRII on naive compared to effector T cells
(Figure 6A; Figure S5A). In fact, on day 5 postinfection, the
expression of TGF-bRII was almost indistinguishable from the
isotype control. However, by about day 7 p.i., the effector cells
began upregulating the surface expression of TGF-bRII, and by
day 15 postinfection, a clear difference was observed between
the amount of TGF-bRII expression on the different subpopula-
tions. The MPECs expressed the highest amount followed by
the double-positive and SLEC subpopulations (Figure 6A;
Figure S5A). Importantly, the expression pattern of TGF-bRII
did not provide a clear explanation for the selective apoptotic
effect of TGF-b on SLECs during clonal expansion; however, it
raised the question as to whether the SLECs are even capableImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 137
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TGF-b Promotes Apoptosis of Effector CD8+ T Cellsof responding to TGF-b around day 7 postinfection. To address
this, we generated in vivo day 7 effector cells (in cotransfer
experiments), recovered these cells, and treated ex vivo half
the recovered splenocytes with recombinant TGF-b, whereas
the other half was just incubated in media without TGF-b for
16 hr (Figure S5B). Apoptotic effect of TGF-b on each effector
subpopulation was determined by measuring the percent of
live cells in TGF-b-treated compared to untreated cells. Interest-
ingly, TGF-b had its greatest apoptotic impact on the OTI
CD127lo subpopulations, whereas it did not impact the OTI
CD127hi subpopulations or the OTI-DNR cells (Figure 6B;
Figure S5C). These data suggest that SLECs can indeed
respond to TGF-b despite the low expression of TGF-bRII on
their surface, and that TGF-b has the same selective apoptotic
effect on the OTI SLEC subpopulation ex vivo as it does in vivo.
TGF-b Antagonizes the Survival Effects of IL-15
on Clonally Expanding T Cells In Vitro
As inflammation subsides around the peak of clonal expansion
and both IL-2 levels and CD25 expression on effector T cells
becomes limiting, theMPECs continue to receive survival signals
through both IL-7 and IL-15, whereas the survival of SLECs
becomes mostly dependent on IL-15, because this population
lacks the expression of IL-7Ra (D’Cruz et al., 2009; Hand et al.,
2007; Joshi et al., 2007). Therefore, we hypothesized that
OTI-DNR SLECs survive better than OTI SLECs, because they
can respond better to IL-15, implying that TGF-b may either
somehow modulate or override the survival signals provided
by IL-15. To test this hypothesis, we wanted to compare the
combinatorial effect of TGF-b and various different cgc cyto-
kines on the survival of effector CD8+ T cells; however, treatment
of in vivo generated effector cells with these cytokines results in
modulation of the perspective receptors (i.e., IL-7 downregulates
IL-7Ra), compromising the analysis on the different subpopula-
tions based on CD127 and KLRG1 expression. Instead, we set
up an in vitro culture assay system to specifically address the
extrinsic effects of TGF-b alone and in combination with the
various cgc cytokines on clonally expanding CD8+ T cells. Naive
CFSE-labeled OTI and OTI-DNR cells were first cocultured with
SIINFEKL peptide-loaded antigen-presenting cells for 48 hr, at
which point OTI and OTI-DNR cells showed similar growth and
cell division (Figure 6C, top). The cells were washed and recul-
tured with either TGF-b alone or with TGF-b in combination
with IL-15, IL-7, or IL-2 for another 4 days (Figure 6C, bottom).
When clonally expanding effector cells were cultured in the pres-
ence of TGF-b, most of the cells in the culture underwent
apoptosis and only about 40% of the cells were recovered
compared to the No TGF-b control (Figure 6C, row labeled
None). As expected, addition of the cgc cytokines greatly
enhanced the recovery of all the cells, and the inclusion of
TGF-b with the OTI-DNR cells had only a modest effect on all
conditions (Figure 6C, right). Most notably, inclusion of TGF-b
with wild-type OTI cells that were cultured in IL-15, compared
to those that were cultured in IL-15 alone, resulted in a similar
low magnitude of cell recovery (about 40%) as OTI cells cultured
in TGF-b alone compared to no TGF-b. However, when cells
were cultured in the presence of TGF-b and IL-7, or TGF-b and
IL-2, about 80% and 100% of the cells, respectively, could still
be recovered compared to the controls (Figure 6C). Thus,138 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.TGF-b has a potent apoptotic effect on clonally expanding
T cells; however, the presence of IL-2 and IL-7 can fully and
partially mask the effects of TGF-b, respectively. Remarkably,
under similar conditions, IL-15 is not able to overcome the
apoptotic effects of TGF-b. Thus, the magnitude of cell death
was similar when cells were cultured with TGF-b alone or with
the combination of IL-15 and TGF-b, whereas IL-7 was able
to protect the clonally expanding T cells from the apoptotic
effects of TGF-b. These observations provide evidence for our
hypothesis that the mechanism by which TGF-b selectively
promotes apoptosis of SLECs is because these cells respond
to IL-15 and not IL-7, whereas MPECs can respond to both
IL-15 and IL-7.
TGF-b and IL-15 Exert Opposing Effects on SLECs
during an Immune Response to Listeria Infection
The cgc cytokines IL-2, IL-7, and IL-15 mediate life and death
signals by activating the Jak-Stat and PI3K survival pathways.
One of the most important outcomes of these signaling path-
ways is regulation of factors such as Bcl-2 and Bim, which deter-
mine survival or death of effector cells (D’Cruz et al., 2009). The
observation that TGF-b can override survival signals provided by
IL-15 but not those provided by IL-7 or IL-2 (Figure 6C) prompted
us to determine whether TGF-b acted on IL-15 signaling, or
whether it promoted the apoptosis of SLECs independent of
this cytokine. To begin addressing this, we first asked whether
OTI-DNR cells biologically respond better to IL-15. In the
absence of exogenous TGF-b, both OTI and OTI-DNR cells
responded similarly to a titration of doses of IL-15 (data not
shown), suggesting that blockade of TGF-b signaling does not
change the sensitivity of their responsiveness to IL-15. In support
of this, we also did not see a difference in the kinetics of phos-
phorylation and dephosphorylation of Stat5 upon stimulation
with different concentrations of IL-15 and in the presence and
absence of TGF-b (data not shown). Subsequently, we also
measured the extent of Akt phosphorylation in response to
IL-15 in OTI and OTI-DNR cells in the presence or absence of
TGF-b, and again did not observe any difference between the
two cell types (data not shown). We concluded from these
studies that TGF-bmost likely was not overriding IL-15 signaling
by inhibiting or dampening the downstream signaling pathways.
Finally, we asked whether TGF-b had an impact on the final
outcome of these signaling events, namely the expression of
Bcl-2 and Bim, whose balance determines the life and death of
short-lived effector T cells (Hildeman et al., 2007; Marrack and
Kappler, 2004;Wojciechowski et al., 2006). To begin, we isolated
mRNA from naive and day 7 effector OTI and OTI-DNR SLECs
and compared the expression of several genes involved in
function, differentiation, and survival of effector CD8+ T cells
(Figure S6). This analysis further validated the absence of
a role for TGF-b in regulating the expression of genes involved
in effector function and differentiation of CD8+ T cells under
these inflammatory conditions. However, we consistently found
a 2-fold increase in the expression of Bcl-2 in OTI-DNR
compared to OTI effector cells, whereas other molecules such
as T-bet remained comparable at both RNA and protein level
(Figures 7A and 7B; Figure S7A). These data suggested that
TGF-b is negatively influencing the expression of Bcl-2 in
effector T cells. Because signaling by the cgc cytokines is the
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Figure 7. TGF-b and IL-15 Control the Number of SLECs by Exerting Opposing Effects on Bcl-2 Levels In Vivo
(A) Quantitative RT-PCR comparing mRNA expression of Bcl-2 and T-bet in sorted naive (prior to adoptive transfer) and effector (day 7 p.i.) OTI and OTI-DNR
SLECs andMPECs. Samples were first normalized to HPRT. Fold change from naive OTI cells is shown. Data are representative of 1 out of 3 independent exper-
iments with similar results.
(B) Intracellular staining of Bcl-2 and T-bet protein in day 7 effector OTI and OTI-DNR subpopulations from a cotransfer experiment. Data are representative of
1 out of 3 independent experiments with similar results.
(C) 2.53 104 each OTI and OTI-DNR cells were cotransferred into either Il-15+/+ or Il-15/ hosts followed by LM-OVA infection. Fraction of total (left) and SLEC
subpopulation (right) of OTI and OTI-DNR cells were determined among total PBLs and converted to numbers of each cell type per 25,000 PBL.
(D) Representation of the difference seen in the percentage of eachOTI andOTI-DNR subpopulations from the spleens of infected Il-15+/+ and Il-15/ hosts at the
indicated time points.
(E) Comparison of intracellular Bcl-2 protein levels in each subpopulation of OTI and OTI-DNR cells isolated from the spleen of Il-15+/+ or Il-15/ hosts.major inducer of Bcl-2 in effector CD8+ T cells, we wanted to
better understand the intertwined relationship between the
survival of SLECs, IL-15, TGF-b, and Bcl-2 expression.
To better understand the in vivo dependence of TGF-b on
IL-15 for promoting apoptosis of SLECs, we began by perform-
ing longitudinal cotransfer experiments comparing the ratio of
OTI and OTI-DNR effector cell subpopulations among total
PBLs in Il15+/+ and Il15/ hosts (Figures 7C–7D; Figures S7B–
S7D). Up to day 5 postinfection, no difference was observed
between the ratios of all OTI and OTI-DNR effector cell subpopu-
lations in both Il15+/+ and Il15/ hosts, suggesting that prolif-
eration and survival of early effector CD8+ T cells in response
to Listeria infection is independent of both TGF-b and IL-15.
This is consistent with a previous report where, with a similar
OTI-LM-OVA infection system, the same numbers of CD127hiand CD127lo OTI cells were found in both Il15+/+ and Il15/
hosts at the peak of the immune response (Yajima et al., 2006).
Starting at around day 6 postinfection, the apoptotic effect of
TGF-b was observed in both Il15+/+ and Il15/ hosts, suggest-
ing that TGF-b can promote apoptosis of clonally expanding
T cells independent of IL-15 signaling. In fact, the magnitude of
the difference between OTI and OTI-DNR SLECs remained the
same in both Il15+/+ and Il15/ hosts up until day 11 postinfec-
tion. However, the absence of IL-15 had a dramatic effect on the
total number of SLECs starting at the peak of clonal expansion
and into the contraction phase (around day 7 p.i.) (Figure 7D;
Figures S8A, S8C, and S8D). In our OTI-LM-OVA system, similar
to previous reports, the clonal expansion of effector cells was not
altered by the absence of IL-15; however, IL-15 was essential for
the survival of effector cells, in particular SLECs, during theImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 139
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Together, these data suggest that in response to Listeria infec-
tion, TGF-b promotes the apoptosis of SLECs during CD8+
T cell clonal expansion independently of IL-15 signaling;
however, the eventual survival of the remaining SLECs during
the contraction phase is dependent on the combination of
prosurvival and proapoptotic effects of IL-15 and TGF-b,
respectively.
TGF-b Dampens Bcl-2 Expression Induced
by IL-15 in SLECs
To address the mechanism by which TGF-b selectively
promotes the apoptosis of SLECs during the contraction phase,
we further explored the combinatorial effect of IL-15 and TGF-b
on Bcl-2 levels. We performed adoptive cotransfer experiments
in Il15+/+ and Il15/ hosts and measured intracellular Bcl-2
expression in each subpopulation of OTI and OTI-DNR effector
cells, focusing on the peak of clonal expansion and contraction,
between days 7 and15 p.i. (Figure 7E; Figure S8B). Once again,
the independence of SLECs on IL-15 up until day 7 p.i. and the
dependence of SLECs on IL-15 during the contraction phase is
depicted in the similarity between cell numbers in Il15+/+ and
Il15/ mice at day 7 p.i. and the dramatic decline of both OTI
and OTI-DNR SLECs in Il15/ hosts by day 12 p.i., respectively
(Figure 7C; Figure S8A, S8C, and S8D). The rapid contraction of
both OTI and OTI-DNR SLECs by day 12 p.i. in Il15/ hosts
correlated with an absence of Bcl-2 expression in this subpopu-
lation in both cell types (Figure 7E; Figure S8B). In the presence
of IL-15, the Bcl-2 continued to slowly rise in SLECs, demon-
strating the dependence of this subpopulation on IL-15 for the
induction of Bcl-2. Importantly, OTI-DNR cells continued to
have twice as much Bcl-2 at all time points in the Il15+/+ hosts,
which also correlated with better survival of OTI-DNR SLECs
during the contraction phase (Figures 7D and 7E). Interestingly,
IL-15 also contributed to the total Bcl-2 amounts in CD127hi
subpopulations (double positives and MPECs) between days 7
and 12 of the contraction phase (Figure 7E; Figure S8B). These
results suggest that IL-15 plays a critical role in promoting the
survival of all effector CD8+ T cells during the early phases of
contraction. IL-15 and IL-7 signaling appear to have an additive
effect on the induction of Bcl-2 in the MPEC subpopulation,
whereas IL-15 signaling alone is responsible for inducing Bcl-2
in the SLEC subpopulation. Taken together, we propose amodel
where TGF-b can inhibit Bcl-2 expression in all effector cell
populations; however, it has its most dramatic effect on SLECs.
Because of their sole dependence on IL-15 for survival signals,
SLECs express very low amounts of Bcl2. By further reducing
the already low amounts of Bcl-2, TGF-b drops the Bcl-2 expres-
sion in SLECs below the threshold of survival, and therefore
selectively promotes apoptosis of this subpopulation (Figure S9).
DISCUSSION
In this study, we addressed the role of TGF-b signaling in effector
CD8+ T cells under infectious conditions with Listeria. We did not
find any differences in OTI function and cell differentiation in
CD11c-DNR versus wild-type hosts; however, we cannot
formally and completely exclude minor contributions from the
CD11c-DNR transgene on our findings. Nevertheless, we140 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.describe that the process of clonal expansion of CD8+ T cells
is a combination of cell proliferation and cell death, and we iden-
tified a role for TGF-b as a key inducer of apoptosis of the short-
lived effector CD8+ T cells during an active immune response.
Our data suggest that both IL-15 and TGF-b are responsible
for controlling the number of short-lived effector CD8+ T cells,
where TGF-b promotes their apoptosis during both clonal
expansion and contraction and IL-15 promotes their survival
during contraction. These findings substantially enhance our
basic knowledge of how the number of effector CD8+ T cells is
regulated in response to an acute infection and emphasizes
the tightly regulated mechanisms involved in the contraction of
effector cells.
The apoptotic effects of TGF-b become apparent around
day 6 after Listeria infection. Several mechanisms can explain
why the early effector cells are not influenced by TGF-b. Under
appropriate inflammatory conditions and upon antigen en-
counter, TCR signaling supports the very early survival and
proliferation of CD8+ T cells. Shortly after, induction of IL-2
promotes the upregulation of CD25 on early effector cells, sup-
porting their further proliferation and differentiation as well as
memory recall response (D’Souza and Lefrancois, 2004;
Williams et al., 2006). When clonally expanding T cells were
cultured in the presence of IL-2 or a combination of IL-2 and
TGF-b, no difference was seen in total numbers of cell recovery
or CFSE dilution. By contrast, when cells were cultured with
IL-15 in combination with TGF-b, cell recovery dropped to 30%
of the recovery seen when cells were cultured with IL-15 alone,
which was mostly due to increased cell death. These data
suggest that IL-2 may be able to overcome the inhibitory and
apoptotic effects of TGF-b and may provide an explanation for
the mechanism by which early effector cells in vivo are not influ-
enced by TGF-b. However, once the infection is resolved and
IL-2 amounts subside, effector CD8+ T cells lose CD25 expres-
sion and their ability to respond to IL-2 is decreased. In the
periphery, downregulation of CD25 is followed by a peak in
CD122 expression around day 4 p.i. Because, in response to
LM-OVA, the absence of IL-15 does not seem to influence the
survival and the overall numbers of effector cells during clonal
expansion, the heightened CD122 expression around day 4 p.i.
may serve to make the effector cells more responsive to residual
amounts of IL-2, thus further protecting them from apoptotic
effects of TGF-b. Interestingly, effector T cells that migrate to
nonlymphoid tissues remain more dependent on IL-2 than those
circulating in lymphoid organs (D’Souza et al., 2002); IL-2may be
the arsenal protecting these effector cells from the apoptotic
effects of TGF-b. Between days 5 and 7, the effector cells
become sensitive to apoptotic affects of TGF-b, in particular
the SLECs that do not express IL-7Ra. Several events likely
contribute to this sensitivity. First, systemic TGF-b amounts go
up, tripling in amount by day 7 postinfection, while at the same
time the majority of the effector population becomes KLRG1hi-
CD127lo and dependent on IL-15 for survival (Joshi et al.,
2007; Yajima et al., 2006). Meanwhile, CD122 and IL-15Ra
amounts that had peaked by day 4 now drop to 40%–50% by
day 7, making the SLECs less able to compete for limiting
amounts of IL-2 and IL-15. The combination of these events
probably shifts the balance between the survival signals that
SLECs can receive and the proapoptotic signals that they
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around the peak of proliferation.
The fact that OTI-DNR cells do contract with similar kinetics as
wild-type OTI cells suggests that another TGF-b-independent
mechanism, such as cytokine withdrawal, is responsible for the
eventual contraction of all effector CD8+ T cells. Comparing
the survival of contracting effector CD8+ T cells in Il15+/+ and
Il15/ hosts, or in the presence of exogenously administered
recombinant IL-15, has highly suggested that IL-15 may be
the factor that determines the ultimate fate of the SLECs, and
our data further support these findings (D’Cruz et al., 2009;
Waldmann, 2006; Yajima et al., 2006).
The activity of the proapoptotic molecule Bim is controlled by
the relative expression of antiapoptotic molecules such as Bcl-2,
Bcl-XL, and MCL-1 and consequently, Bcl-2 and MCL-1 have
been shown to be necessary for the survival of memory T cells
(Opferman et al., 2003; Wojciechowski et al., 2007). Bcl-2 is
downregulated at the peak of infection in activated T cells, and
transgenic expression of Bcl-2 can rescue T cells from contrac-
tion (Hildeman et al., 2002; Pellegrini et al., 2003). It is thought
that cgc cytokines promote the survival of effector T cells by
inducing the expression of Bcl-2 (Nakajima et al., 1997; Vella
et al., 1998). We observed much higher Bcl-2 expression in
MPECs compared to SLECs during early contraction, which
seemed to be the result of signaling induced by both IL-7 and
IL-15. However, toward the latter part of the contraction phase,
Bcl-2 expression in SLECs remained nonexistent in Il15/ hosts
and low in Il15+/+ hosts and Bcl-2 expression stayed high in
MPECs and became equivalent in both Il15+/+ and Il15/ hosts,
suggesting that IL-7 eventually becomes the major source of
Bcl-2 induction for MPECs. Similar to forced expression of
Bcl-2, administration of IL-2, IL-7, or IL-15 can prevent the
apoptosis of both CD127hi and CD127lo effector T cells during
contraction (Rubinstein et al., 2008; Yajima et al., 2006). This
indirectly suggests that toward the middle of the contraction
phase, IL-15 becomes limiting even in the Il15+/+ hosts, thereby
further limiting the only Bcl-2-inducing signal that SLECs receive.
Meanwhile, the 2-fold impact of TGF-b on Bcl-2 expression
becomes much more critical for the SLEC population compared
to the MPEC population, causing the already low expression of
Bcl-2 to fall below the survival threshold, which ultimately results
in the selective apoptosis of SLECs. This model reconciles our
current data and provides an explanation for the selective impact
TGF-b has on promoting the apoptosis of SLECs during contrac-
tion, while allowing the survival and differentiation of MPECs.
TGF-b is synthesized as an inactive latent form that is unable
to bind to its receptor. This suggests that high levels of TGF-b
in plasma, possibly produced by effector T cells, T regulatory
cells, or antigen-presenting cells, do not necessarily translate
to a systemic increase in TGF-b responsiveness. Notably, the
cells that can activate TGF-b may also be different than those
that produce this potent cytokine, and thus this activation step
provides a means for TGF-b to integrate signals from multiple
cell types (Li and Flavell, 2008a, 2008b). Dendritic cells (DCs)
may play a role in activating T cell-produced TGF-b through
their surface-expressed avb8 integrin (Li and Flavell, 2008a;
Travis et al., 2007). In addition, DCs have been suggested to
be the prominent source of trans-presented IL-15 during acute
infection, as indicated by the fact that they upregulate theIL-15-IL-15Ra complex in response to inflammatory stimuli
(Dubois et al., 2002; Waldmann, 2006). It is therefore plausible
to hypothesize that another mechanism whereby TGF-b selec-
tively induces apoptosis of SLECs relates to the means by which
these cells come in contact with trans-presented IL-15, which
brings them into the vicinity of avb8 integrins expressed on the
surface of DCs. As a result, the latent form of TGF-b that is
abundantly available in plasma during the peak of infection, or
made by either the DC or the effector T cell itself, may become
locally activated by the avb8 integrins. This model would
suggest that as the SLECs come in contact with DCs to receive
a survival signal through trans-presented IL-15, they also
become simultaneously exposed to active form of TGF-b in the
same local environment. In contrast, because the MPECs can
rely on both trans-presented IL-15 and soluble IL-7 for survival,
they can receive survival signals through IL-7 signaling without
exposing themselves to the active forms of TGF-b that poten-
tially exists in the local environment near the trans-presented
IL-15 on DCs.
The current findings in this study have several potentially
important clinical implications. Autoimmunity and inflammatory
diseases can be caused by decreased immune suppression,
whereas cancers and certain infectious diseases are often asso-
ciated with increased immune suppression. Induction of TGF-
b-producing regulatory T cells has been associated with better
prognosis in several autoimmune diseases. For example,
a promising immunotherapy for type 1 diabetes (T1D) involves
the administration of a CD3-specific monoclonal antibody (Her-
old et al., 2002), which functions by eliminating autoreactive
T cells and promoting the expansion of TGF-b-producing regula-
tory T cells (Chatenoud and Bluestone, 2007). Our data suggest
that a mechanism by which this immunotherapy may function is
through a TGF-b-dependent induction of apoptosis of self-reac-
tive effector T cells. Such depleting immunotherapy also gener-
ates a lymphopenic environment where IL-15 presumably
becomes highly abundant. We therefore would predict that
neutralization of IL-15 under such lymphopenic conditions may
help to further destabilize self-reactive effector T cells whose
survival may be dependent on IL-15. Targeting IL-15 as a means
of immunotherapy against many autoimmune diseases has been
suggested and is currently under trial (Waldmann, 2006). Our
findings in this study support and provide further mechanistic
insights into the success of a combinatorial therapy of simulta-
neously inducing TGF-b and blocking IL-15 to achieve the best
immunotherapeutic results against T1D.
Elimination of most tumors by the immune system involves
functional CD8+ cytotoxic T lymphocytes. Studies in our labora-
tory and by other investigators provide compelling evidence that
inhibition of TGF-b signaling may address several key mecha-
nisms of resistance and improve the efficacy of tumor immune
therapy (Gorelik and Flavell, 2001; Wrzesinski et al., 2007). In
the current study we describe a mechanism whereby tumors
may prevent their immune-mediated destruction by producing
TGF-b and directly promoting the apoptosis of tumor antigen-
specific effector CD8+ T cells. In addition, many studies have
already demonstrated the efficacy of therapeutic uses of IL-15
for eradicating tumors (Klebanoff et al., 2004; Morris et al.,
2006). Our findings strongly support these notions and provide
a cellular mechanism by which the combinatorial effects ofImmunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc. 141
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have the most beneficial therapeutic outcomes during vaccina-
tion or tumor immunotherapy. Such combinatorial therapy would
most likely lead to enhanced numbers of effector CD8+ SLECs as
well as CD4+ Th1 cells (Li et al., 2006a).
EXPERIMENTAL PROCEDURES
Mice
CD4-TGF-bRII-DNR mice (Gorelik and Flavell, 2000) were bred on to OTI Va2/
Vb5 TCR transgenic specific for OVA257-264 that recognizes SIINFEKL epitope
in the context of MHC class I H-2Kb. Thesemice were then crossed toRag1/
(JAX) and CD45.1 (NCI) congenic markers. CD11c-DNR transgenic mice
(Laouar et al., 2005) were maintained on a C57BL/6 background. Il-15/
mice were purchased from Taconic and bred onto the CD11c-DNR mice.
All animal experimentation was conducted in accordance with institutional
guidelines.
Adoptive Cotransfer and LM-OVA Infection
Every cotransfer experiment consisted of 1.5–2.5 3 104 sorted naive OTI and
OTI-DNR cells each on a different congenic marker mixed at a 1:1 ratio. One to
two days after adoptive transfer, mice were infected with 13 105 recombinant
Listeria monocytogenes, expressing OVA (LM-OVA), which was a generous
gift from H. Shen (U. Penn).
Isolation of Peripheral Blood Lymphocytes and Calculating Cell
Populations among PBLs
100–150 ml of blood from tail vein of infected mice was added to 30 ml of
13 heparin (500 units/ml). 500 ml of 13 ACK lysis buffer (Lonza) was added
directly to the cells and incubated at room temperature for 2–3 min. Cells
were centrifuged at 4000 rpm for 5 min. The top layer was aspirated and
another 500 ml of 13 ACK lysis buffer was added followed by centrifugation.
Cells were resuspended in 500 ml of FACS buffer (PBS + 0.5% FBS)
and divided into 2–4 wells of a 96-well V-bottom plate and stained with
surface antibodies. The same gate was set on a FACS Calibur machine to
collect 25,000 live lymphocytes for every time point. The same gate was
also set during analysis of the data, and thus the starting number of PBLs
was set to 25,000 for every calculation. Total number of host CD8+ T cells
was measured as an internal control, which remained roughly around 4,000/
25,000 in early and late time points, but increased to 5,000–6,000 at the
peak of T cell proliferation. Based on the frequencies obtained from FACS
analysis, we then calculated the number of each subpopulation out of
25,000 PBLs.
Isolation of Lymphocytes from Nonlymphoid Organs
Peripheral blood was isolated from tail vein of infected mice as described
above. Mice were then euthanized and perfused with 30 mL of cold PBS to re-
move all the blood from the liver and lung. Liver and lung were removed, and
cell homogenates were digested for 1 hr at 37C with digestion buffer (RPMI +
5%FBS+ 100U/ml DNase I [Sigma] + 0.2mg/ml Collagenase D [Roche]). Liver
homogenates were centrifuged at 300 rpm for 3 min to remove hepatocytes,
and lung homogenates were run through a 70 mm filter mesh. Nonhepatic
supernatant and lung lymphocytes were centrifuged at 1500 rpm for 10 min.
The cell pellet was resuspended in 1 ml of RPMI + 5% FBS and mixed with
4 ml of 27.5% OptiPrep (Axis-Shield; Oslo, Norway). To make a gradient,
1 ml of RPMI was carefully layered on top of the cells and centrifuged at
2700 rpm for 20 min. Lymphocytes were carefully removed from the interface
of the gradient and further analyzed.
Antibodies and Reagents
All FACS antibodies used were from BD PharMingen, except for Biotin or
PE-CD127 (eBioscience), APC KLRG1 (eBioscience), APC Granzyme B
(CALTAG), PE T-bet (eBioscience), Biotin IL-15Ra (R&D Systems), and PE
TGF-bRII and isotype control (R&D Systems). Recombinant cytokines mouse
IL-15 (R&D Systems), mouse IL-7 (PeroTech Inc.), mouse IL-2 (BD PharMin-
gen), and human TGF-b1 (R&D Systems) were used.142 Immunity 31, 131–144, July 17, 2009 ª2009 Elsevier Inc.Measuring Plasma TGF-b1
100–200 ml of tail-vein bloodwas collected and immediately mixedwith 30 ml of
25 mM EDTA and immediately put on ice. Samples were centrifuged at 3,000
rpm for 5 min. Plasma was removed, transferred to a new tube, and spun
again at 12,000 rpm for 5 min to remove residual RBCs and platelets. Plasma
samples were kept at 70C for future use. TGF-b1 Emax ImmunoAssay
System (Promega) was used to measure TGF-b1. Plasma samples were
acid treated to activate total TGF-b per manufacturer’s instructions. Non-
acid-treated samples were diluted 2-fold in the provided 13 Sample Buffer.
BrdU Labeling and AnnexinV + PI Staining
Mice were injected intraperitoneally with a single dose of 1 mg BrdU (5-bromo-
deoxyuridine; Sigma) on day 6 postinfection. Spleens were harvested 14 hr
later and stained first for surface markers. Cells were fixed and permeabilized
overnight in 100 ml of 1% PFA + 0.01% Tween 20 at 4C. Cells were then
treated with DNase I (Sigma) at 37C for 60 min. FITC anti-BrdU Ab (BD) was
used to detect cells that had incorporated BrdU. Annexin V-FITC and -APC
Apoptosis Detection Kit I (BD PharMingen) was used per manufacturer’s
instructions.
Intracellular Cytokine Staining
Splenocytes from day 7 infected mice were incubated with 20 mMof SIINFEKL
peptide in the presence of BD GolgiStop for 5 hr at 37C in CO2 incubator. BD
Cytofix/Cytoperm was used to stain for intracellular cytokines, Granzyme B,
Bcl-2, and T-bet.
In Vivo CTL Assay
OTI and OTI-DNR day 7 effector cells were purified by cell sorting andmixed at
various ratios with CFSE-labeled target cells as previously described (Ingulli,
2007). The mixture of effector and target cells were injected i.v. into naive
hosts. 14–16 hr later, spleens from the recipient mice were harvested and
the ratio of CFSEhi and CFSElo cells was measured by FACS analysis as previ-
ously described (Ingulli, 2007).
In Vitro T Cell Cultures and Cell Recovery Assay
Naive OTI and OTI-DNR CD8+ T cells were purified by cell sorting. 100 3 106
splenocytes were incubated with 200 nM of SIINFEKL peptide at 37C for 1 hr
followed by 2 washes. 3–5 3 106 naive cells were mixed with 30–50 3 106
peptide-loaded splenocytes and the mixture was labeled with 5 mM of
CFSE. Cells were cultured for 2 days in Complete media (Clicks, 10% FBS,
L-Glutamine, BME, pen/strep) in the presence of peptide-loaded APCs. Cells
were then washed andmixed again with naive live splenocytes in the presence
of various cytokines as indicated. Two days later, one half of the media was
removed and replenished with fresh media and cytokines. After a total of
6 days (2 days with peptide and 4 days with cytokines), cells were harvested
and stained with PE CD45.1, Percp CD8, and APC-AnnexinV. Cells were
kept on ice at all times and resuspended in the same final volume before
FACS analysis. To determine the total number of recovered cells, each sample
was collected on FACS Calibur for exactly 1 min.
Statistical Analysis
Student’s t test (two-tailed) was used to calculate the statistical significance of
data comparison. p value of% 0.05 was considered to be significant.
SUPPLEMENTAL DATA
Supplemental Data include nine figures and can be found with this article on-
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